|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2600122076 |
|
最近更新日期: Date of Last Refreshed on: |
2026-04-08 17:22:05 |
|
注册时间: Date of Registration: |
2026-04-08 00:00:00 |
|
注册号状态: |
补注册 |
|
Registration Status: |
Retrospective registration |
|
注册题目: |
基于HAPA理论的高尿酸血症患者自我管理健康教育方案的构建及应用 |
|
Public title: |
Construction and application of a self-management health education program for patients with hyperuricemia based on HAPA theory |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
基于HAPA理论的高尿酸血症患者自我管理健康教育方案的构建及应用 |
|
Scientific title: |
Construction and application of a self-management health education program for patients with hyperuricemia based on HAPA theory |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
贾优 |
研究负责人: |
葛珊珊 |
|
Applicant: |
Jia You |
Study leader: |
Ge Shanshan |
|
申请注册联系人电话: Applicant telephone: |
+86 172 0058 9577 |
研究负责人电话:
Study leader's |
+86 139 3460 3635 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
17200589577@163.com |
研究负责人电子邮件: Study leader's E-mail: |
geshanshan1@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
山西省太原市迎泽区迎泽街道新建南路56号 |
研究负责人通讯地址: |
山西省太原市迎泽区解放南路85号 |
|
Applicant address: |
No. 56, Xiangjian South Road, Yingze Subdistrict, Yingze District, Taiyuan City, Shanxi Province |
Study leader's address: |
No. 85, Jiefang South Road, Yingze District, Taiyuan City, Shanxi Province |
|
申请注册联系人邮政编码: Applicant postcode: |
030001 |
研究负责人邮政编码: Study leader's postcode: |
030001 |
|
申请人所在单位: |
山西医科大学 |
||
|
Applicant's institution: |
Shanxi Medical University |
||
|
研究负责人所在单位: |
山西医科大学第一医院 |
||
|
Affiliation of the Leader: |
First Hospital of Shanxi Medical University |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
KYLL-2025-320 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
山西医科大学第一医院科学研究伦理审查委员会 |
||
|
Name of the ethic committee: |
The Scientific Research Ethics Review Committee of the First Hospital of Shanxi Medical University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2025-08-15 00:00:00 | ||
|
伦理委员会联系人: |
智陞雯 |
||
|
Contact Name of the ethic committee: |
Zhi Shengwen |
||
|
伦理委员会联系地址: |
山西省太原市迎泽区解放南路85号 |
||
|
Contact Address of the ethic committee: |
No. 85, Jiefang South Road, Yingze District, Taiyuan City, Shanxi Province |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 351 463 9021 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
山西医科大学第一医院 |
||||||||||||||||||||||
|
Primary sponsor: |
The First Hospital of Shanxi Medical University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
山西省太原市迎泽区解放南路85号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No. 85, Jiefang South Road, Yingze District, Taiyuan City, Shanxi Province |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
由研究生、研究生导师及科室自筹。 |
||||||||||||||||||||||
|
Source(s) of funding: |
It is funded by graduate students, their supervisors, and the department itself. |
||||||||||||||||||||||
|
研究疾病: |
高尿酸血症 |
||||||||||||||||||||||
|
Target disease: |
hyperuricemia |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
1. 构建基于 HAPA 理论的高尿酸血症患者自我管理健康教育方案的构建及应用。 2. 探讨该方案在高尿酸血症患者中的应用效果。 |
||||||||||||||||||||||
|
Objectives of Study: |
1. Construction and application of self-management health education program for patients with hyperuricemia based on HAPA theory. 2. To explore the application effect of this program in patients with hyperuricemia. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1.年龄18~59岁的中青年;; 2.符合《中国高尿酸血症相关疾病诊疗多学科专家共识(2023年版)》[1]中高尿酸血症的诊断标准:成人在正常嘌呤饮食情况下,不分男女,非同日2次空腹血尿酸水平超过420mol/L; 3.对本研究知情同意且自愿参与者; 4.拥有智能手机并能熟练操作微信软件者; 5.患者具有良好的沟通和理解能力,能独立或通过他人协助配合完成本研究。 |
||||||||||||||||||||||
|
Inclusion criteria |
1. Young and middle-aged people aged 18-59 years;; 2. Meet the diagnostic criteria of hyperuricemia in the "Chinese Multidisciplinary Expert Consensus on the diagnosis and treatment of hyperuricemia related Diseases (2023 version)" [1] : adults with normal purine diet, regardless of men and women, fasting blood uric acid level more than 420mol/L twice on different days; 3.Informed consent and voluntary participants; 4. have a smart phone and can skillfully operate wechat software; 5. Patients have good communication and understanding skills, and can complete the study independently or with the assistance of others. |
||||||||||||||||||||||
|
排除标准: |
1.严重创伤病史、心肝肾等重要脏器功能不全、脑血管病变、恶性肿瘤等患者; 2.急性痛风发作期; 3.存在认知功能损害或严重精神障碍,无法配合研究的患者; 4.同时参与其他同类研究的临床受试者。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1. Patients with history of severe trauma, heart, liver, kidney and other important organ dysfunction, cerebrovascular disease, malignant tumors, etc. 2. Acute gout attack; 3. Patients with cognitive impairment or severe mental disorder who are unable to cooperate with the study; 4. Clinical subjects participating in other similar studies at the same time. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2025-08-18 00:00:00至 To 2026-06-30 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2025-08-18 00:00:00 至 To 2025-09-19 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
结束 /Completed |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
由研究者对使用 Excel 软件中的 Rand 函数生成70个0到1之间的随机数,每个序号对应一个随机数,将其按照从小到大的顺序均分为A(对照组)、B(干预组)两组。 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
The researchers used the Rand function in Excel to generate 70 random numbers ranging from 0 to 1. Each number corresponded to a specific sequence. These numbers were then evenly divided into two groups, A (control group) and B (intervention group), in ascending order. |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
本研究采用单盲法。在不透明的密闭信封中标明序号和组别(A 或 B),由不参与患者评估、干预实施及数据收集的研究人员负责制作分组信封。采用便利抽样法,根据患者入科体检的顺序依次发放信封,将符合纳排标准的 70 名患者随机分配至两组。 施盲对象为研究对象,患者在整个研究过程中均不知晓自己所属的组别及干预方案;干预实施者、资料收集者及数据分析人员未实施盲法。 |
|
Blinding: |
This study employed a single-blind method. The serial numbers and groups (A or B) were indicated on opaque sealed envelopes, which were prepared by researchers who were not involved in patient assessment, intervention implementation, and data collection. The convenience sampling method was used, and envelopes were distributed in sequence based on the patients' admission physical examination order. A total of 70 patients meeting the inclusion and exclusion criteria were randomly assigned to the two groups. The subjects were the research participants. Throughout the entire study, the patients were unaware of their assigned group and the intervention plan; the intervention implementers, data collectors, and data analysts did not follow the blind method. |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
是Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
ResManl临床试验公共管理平台 http://www.medresman.org.cn/login.aspx 试验结束六个月内分享 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
http://www.medresman.org.cn/login.aspx Sharing within six months of the end of the trial |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
CRF |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
CRF |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
有/Yes |